238 related articles for article (PubMed ID: 15679069)
21. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model.
Rissanen JP; Suominen MI; Peng Z; Halleen JM
Calcif Tissue Int; 2008 Feb; 82(2):108-15. PubMed ID: 18084692
[TBL] [Abstract][Full Text] [Related]
22. A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum.
Alatalo SL; Peng Z; Janckila AJ; Kaija H; Vihko P; Vaananen HK; Halleen JM
J Bone Miner Res; 2003 Jan; 18(1):134-9. PubMed ID: 12510815
[TBL] [Abstract][Full Text] [Related]
23. [Development for the determination of band 5b tartrate-resistant acid phosphatase activity in serum].
Uchida K; Nakanishi M; Yoh K
Rinsho Byori; 2001 Jan; 49(1):51-5. PubMed ID: 11215484
[TBL] [Abstract][Full Text] [Related]
24. Alternative immunoassay for tartrate-resistant acid phosphatase isoform 5b using the fluorogenic substrate naphthol ASBI-phosphate and heparin.
Janckila AJ; Simons RM; Yam LT
Clin Chim Acta; 2004 Sep; 347(1-2):157-67. PubMed ID: 15313154
[TBL] [Abstract][Full Text] [Related]
25. Tartrate-resistant acid phosphatase 5b is a potential biomarker for rheumatoid arthritis: a pilot study in Han Chinese.
Cheng T; Wang M; Chen Z; Eisenberg RA; Zhang Y; Zou Y; Deng Y; Wang M; Zhou L
Chin Med J (Engl); 2014; 127(16):2894-9. PubMed ID: 25131223
[TBL] [Abstract][Full Text] [Related]
26. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
[TBL] [Abstract][Full Text] [Related]
27. Altered levels of BMD, PRL, BAP and TRACP-5b in male chronic patients with schizophrenia.
Du X; Ye F; Li J; Zhao Y; Xiao W; Tang X; Zhang X
Sci Rep; 2020 Aug; 10(1):13598. PubMed ID: 32788631
[TBL] [Abstract][Full Text] [Related]
28. TRACP 5b and CTX as osteological markers of delayed fracture healing.
Moghaddam A; Müller U; Roth HJ; Wentzensen A; Grützner PA; Zimmermann G
Injury; 2011 Aug; 42(8):758-64. PubMed ID: 21168135
[TBL] [Abstract][Full Text] [Related]
29. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
[TBL] [Abstract][Full Text] [Related]
30. Tartrate-resistant acid phosphatase isoform 5a as an inflammation marker in end-stage renal disease.
Janckila AJ; Lederer ED; Price BA; Yam LT
Clin Nephrol; 2009 Apr; 71(4):387-96. PubMed ID: 19356371
[TBL] [Abstract][Full Text] [Related]
31. Specificity and clinical performance of two commercial TRACP 5b immunoassays.
Ylipahkala H; Fagerlund KM; Janckila AJ; Houston B; Laurie D; Halleen JM
Clin Lab; 2009; 55(5-6):223-8. PubMed ID: 19728556
[TBL] [Abstract][Full Text] [Related]
32. Tartrate-resistant acid phosphatase 5B circulates in human serum in complex with alpha2-macroglobulin and calcium.
Ylipahkala H; Halleen JM; Kaija H; Vihko P; Väänänen HK
Biochem Biophys Res Commun; 2003 Aug; 308(2):320-4. PubMed ID: 12901871
[TBL] [Abstract][Full Text] [Related]
33. Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.
Okuno S; Ishimura E; Tsuboniwa N; Norimine K; Yamakawa K; Yamakawa T; Shoji S; Mori K; Nishizawa Y; Inaba M
Osteoporos Int; 2013 Feb; 24(2):605-12. PubMed ID: 22581293
[TBL] [Abstract][Full Text] [Related]
34. [Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients].
Shiota J; Izumi N; Kasahara H; Tagawa H; Chiba T; Nihei H
Nihon Jinzo Gakkai Shi; 2010; 52(8):1022-8. PubMed ID: 21254698
[TBL] [Abstract][Full Text] [Related]
35. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
36. Reference intervals of serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects.
Nishizawa Y; Inaba M; Ishii M; Yamashita H; Miki T; Goto H; Yamada S; Chaki O; Kurasawa K; Mochizuki Y
J Bone Miner Metab; 2008; 26(3):265-70. PubMed ID: 18470668
[TBL] [Abstract][Full Text] [Related]
37. Analytical evaluation of the Nittobo Medical tartrate resistant acid phosphatase isoform 5b (TRACP-5b) EIA and comparison with IDS iSYS in different clinically defined populations.
Cavalier E; Lukas P; Delanaye P
Clin Chem Lab Med; 2022 Feb; 60(3):394-400. PubMed ID: 34907694
[TBL] [Abstract][Full Text] [Related]
38. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
39. Significance of serum TRACP in rheumatoid arthritis.
Janckila AJ; Neustadt DH; Yam LT
J Bone Miner Res; 2008 Aug; 23(8):1287-95. PubMed ID: 18410226
[TBL] [Abstract][Full Text] [Related]
40. [Tartrate resistant acid phosphatase--TRACP-5b as a modern bone resorption marker].
Nowak Z; Konieczna M; Saracyn M; Wańkowicz Z
Pol Merkur Lekarski; 2008 Apr; 24(142):351-4. PubMed ID: 18634372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
